Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Werewolf Therapeutics (HOWL – Research Report), with a price target of $10.00.

Jason Zemansky has given his Buy rating due to a combination of factors including the optimistic outlook conveyed by Werewolf Therapeutics’ management in a recent investor call regarding their PREDATOR platform. The company’s phase 1 candidate, ‘124, has shown early signs of efficacy in cytokine refractory patients, indicated by a dose response and T-cell activation consistent with pre-clinical expectations. Furthermore, the upcoming interim data is anticipated to provide additional insight into the candidate’s performance, despite the challenges associated with interpreting results from a heterogeneous dose-escalation population.

Werewolf Therapeutics also presented a compelling case for the commercial potential of ‘124 beyond its current indications, with a focus on its use in a wide range of immunotherapy-sensitive tumors and in combination with other standard-of-care therapies. Additionally, positive safety data for their IL-12 candidate ‘330 could significantly de-risk this asset, which has shown promise for treating less immunogenic tumors. Moreover, the company’s early-stage platform candidates, particularly ‘712 (IL-21) with its robust anti-tumor activity, suggest potential for strong combination therapies. These factors underpin Zemansky’s continued support for a Buy rating and a price objective of $10.00 for Werewolf Therapeutics’ stock.

In another report released on April 10, JMP Securities also reiterated a Buy rating on the stock with a $12.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Werewolf Therapeutics (HOWL) Company Description:

Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.